Investment
Features
FeesSafety
Academy
More
Pluang+

Compare H World Group Limited American Depositary Shares (HTHT) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance

H World Group Limited American Depositary SharesTrade
Nuvation Bio Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

H World Group Limited American Depositary Shares vs Nuvation Bio Inc. Class A Common Stock — how do they compare? H World Group Limited American Depositary Shares trades at $44.06 (market cap $13.25B), while Nuvation Bio Inc. Class A Common Stock trades at $4.96 (market cap $1.74B). The key difference: H World Group Limited American Depositary Shares is far larger — about 7.6× Nuvation Bio Inc. Class A Common Stock's market cap, and H World Group Limited American Depositary Shares pays a 5.08% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold H World Group Limited American Depositary Shares for 0 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.

HTHTNUVB
Market Cap
$13.25B$1.74B
Volume
1,177,2619,289,619
Sector
Consumer CyclicalHealth
52-Week High
$56.06$9.54
52-Week Low
$36.99$3.41
Typical Hold Time
0 Days0 Days
Enterprise Value
$16.03B$1.33B
Dividend Yield
5.08%—

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HTHT
100% Buy0% Sell
Avg holding period · 0 Days
NUVB
100% Buy0% Sell
Avg holding period · 0 Days

About H World Group Limited American Depositary Shares

H World Group operates hotels through leased and owned, managed franchise, and franchise models. Its brands include HanTing, JI Hotel, Orange Hotel, and Steigenberger Hotels & Resorts.

Read more on HTHT →

About Nuvation Bio Inc. Class A Common Stock

Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.

Read more on NUVB →